Dexmedetomidine for Preventing Postoperative Delirium and a Risk Prediction Nomogram in Older Adults Undergoing Gastrointestinal Surgery
Key facts
- Who runs it
- Hanoi Medical University
- Where
- Vietnam1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 630 people, planned
- Starts
- 1 Dec 2026
- Expected to end
- 30 Apr 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Dexmedetomidine
- Placebo
- Record updated
- 17 November 2026
Who can take part
- Age
- 60 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age 60 years or older
- Scheduled for elective gastrointestinal surgery (esophageal, gastroduodenal, small bowel, colorectal, hepatobiliary, pancreatic or splenic) under general anesthesia
- American Society of Anesthesiologists (ASA) physical status I-III
- Written informed consent from the patient, or from a legally authorized representative if the patient lacks decision-making capacity
Who cannot take part
- Expected duration of surgery < 90 minutes
- Substance dependence or abuse, or current use of antipsychotic medication
- Refusal by the patient or family to participate; Withdrawal criteria (after randomization): severe anesthetic or surgical complications (e.g., anaphylaxis, local anesthetic systemic toxicity, hemorrhagic shock); premature discontinuation of study drug due to adverse effects; actual surgical duration < 90 minutes; postoperative mechanical ventilation > 24 hours; re-anesthesia, spinal anesthesia or reoperation during the study period; withdrawal of consent. Patients withdrawn after starting the infusion remain in the mITT analysis
- Severe preoperative cognitive impairment (Mini-Mental State Examination score < 14)
- Contraindications to dexmedetomidine: known allergy, bradycardia, second- or third-degree atrioventricular block without a pacemaker, or current high-dose beta-blocker therapy
- Hepatic failure (Child-Pugh class B or C) or end-stage renal disease requiring dialysis
- Cancer with brain or bone metastases causing severe preoperative pain
- Preoperative delirium
- Communication difficulties preventing completion of study assessments
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Postoperative delirium (POD) is a common and serious complication in older adults after major gastrointestinal surgery and is associated with longer hospital stay, long-term cognitive decline and higher mortality. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist with sedative, anti-inflammatory and opioid-sparing effects, may reduce POD, but evidence in older patients undergoing gastrointestinal surgery remains inconsistent, and tools to identify which patients are at highest risk are lacking.
Read full original descriptionShow less
The goal of this randomized, double-blind, placebo-controlled trial is to learn whether intraoperative and early postoperative dexmedetomidine prevents POD in patients aged 60 years or older undergoing elective gastrointestinal surgery under general anesthesia, and to develop a risk prediction nomogram for POD in this population. The main questions it aims to answer are:
1. Does dexmedetomidine lower the incidence of POD within 5 days after surgery compared with placebo, and is it safe? 2. How accurately can a prediction model (nomogram) built from preoperative and intraoperative factors estimate each patient's risk of POD?
Researchers will also examine how dexmedetomidine changes postoperative inflammatory and stress markers (IL-6, cortisol, CRP, NLR, SII) and their association with POD, and whether the benefit of dexmedetomidine differs across baseline-risk strata.
Participants will be randomly assigned to dexmedetomidine or placebo (0.9% saline). The blinded infusion starts 15 minutes before induction of anesthesia (dexmedetomidine 0.5 mcg/kg over 15 minutes, then 0.5 mcg/kg/h until 2 hours after surgery, or the same volume and rate of saline). Delirium will be assessed three times daily with the 3D-CAM (or CAM-ICU for patients who cannot be interviewed) from the end of surgery until postoperative day 5 or hospital discharge.
The 2 groups in the trial
- DexmedetomidineTreatment being tested
Dexmedetomidine 4 mcg/mL (200 mcg in 50 mL 0.9% saline). Loading dose 0.5 mcg/kg infused over 15 minutes starting 15 minutes before induction of general anesthesia, followed by a maintenance infusion of 0.5 mcg/kg/h throughout surgery until 2 hours after the end of surgery.
- Placebo (0.9% saline)Placebo, for comparison
0.9% sodium chloride 50 mL in an identical syringe, infused at the same volume, rate and duration as the dexmedetomidine arm (15-minute loading infusion before induction, then maintenance until 2 hours after the end of surgery).
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Dexmedetomidine in Preventing Postoperative Delirium and a Risk Prediction Nomogram in Geriatric Patients Undergoing Gastrointestinal Surgery: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial
- Record updated
- 17 November 2026